Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

NCT02896127 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

458

Enrollment

INDUSTRY

Sponsor class

Conditions

Ankylosing Spondyloarthritis

Interventions

DRUG: Secukinumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals